Otros idiomas Xintela AB

Acciones

Mercado cerrado - Nasdaq Stockholm Otros sitios de cotización 18:00:00 25/06/2024			Varia. Cinco días.	Varia. 1 de enero.
0,3 ^SEK	0,00 %		+8,70 %	+10,70 %

24/05	Xintela AB (publ) comunica los resultados del primer trimestre finalizado el 31 de marzo de 2024	CI
23/05	Xintela y EQGen Biomedical colaborarán en el desarrollo del tratamiento con células madre para caballos EQSTEM	CI

Xintela: Closing in on the first license agreement	29/05
Xintela AB Interim Report January - March 2024	24/05
Xintela AB Reports Earnings Results for the First Quarter Ended March 31, 2024	24/05
Xintela and EQGen Biomedical to collaborate to develop EQSTEM stem cell treatment for horses	23/05
Xintela and EQGen Biomedical to Collaborate to Develop EQSTEM Stem Cell Treatment for Horses	23/05
Xintela AB publishes Annual Report 2023	17/04
Xintela: Awaiting results in trials and discussions	29/02
Xintela AB Year-end Report 2023	28/02
Xintela AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Xintela Names New Chief Scientific Officer	20/02
Xintela appoints Lucienne Vonk as Chief Scientific Officer	19/02
Xintela Appoints Lucienne Vonk as Chief Scientific Officer	19/02
Targinta's CEO to BioStock: "Strong interest in ADCs in 2023"	22/01
Xintela newsletter, No. 1 2024	19/01
First patient dosed in Xintela's clinical study on difficult-to-heal leg ulcers	21/12
Xintela AB Announces First Patient Dosed in It's Clinical Study on Difficult-To-Heal Leg Ulcers	21/12
Xintela publishes efficacy results with EQSTEM from preclinical equine OA study	20/12
Xintela Publishes Efficacy Results with EQSTEM from Preclinical Equine OA Study	20/12
Västra Hamnen Corporate Finance initiates coverage of Xintela	04/12
Xintela’s integrin marker carries hidden value	01/12

No hay resultados para esta búsqueda